or Try an Advanced Search...

    Technical Analysis for RAPT - RAPT Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.88 -5.57% -0.17
    RAPT closed down 5.57 percent on Monday, July 1, 2024, on 41 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical RAPT trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Pocket Pivot Bullish Swing Setup -5.57%
    New 52 Week Low Weakness -5.57%
    Wide Bands Range Expansion -5.57%
    Oversold Stochastic Weakness -5.57%
    New 52 Week Closing Low Bearish -0.35%
    180 Bearish Setup Bearish Swing Setup -0.35%
    Older End-of-Day Signals for RAPT ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 5 hours ago
    Possible NR7 about 6 hours ago
    Down 2 % about 9 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    10 DMA Resistance about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    RAPT Chart by TradingView
    Basic chart:

    Profile

    RAPT Therapeutics, Inc. Description

    RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Disease Immunology Pharmacy Treatment Of Cancer Tumor Inflammatory Diseases Specialty Drugs Small Molecule Therapies Immune Response

    Is RAPT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 21 Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
    Jun 14 Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
    May 29 Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
    May 20 RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
    May 14 Wolfe downgrades RAPT, but still sees "immense" upside potential
    May 13 Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
    May 12 Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
    May 10 RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview
    May 10 RAPT falls for second day as Guggenheim, Barclays downgrade stock
    May 9 What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
    See more RAPT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 27.35
    52 Week Low 2.81
    Average Volume 733,647
    200-Day Moving Average 13.09
    50-Day Moving Average 4.97
    20-Day Moving Average 3.44
    10-Day Moving Average 3.09
    Average True Range 0.29
    RSI (14) 26.47
    ADX 39.38
    +DI 12.45
    -DI 32.33
    Chandelier Exit (Long, 3 ATRs) 3.74
    Chandelier Exit (Short, 3 ATRs) 3.67
    Upper Bollinger Bands 4.24
    Lower Bollinger Band 2.64
    Percent B (%b) 0.15
    BandWidth 46.55
    MACD Line -0.55
    MACD Signal Line -0.62
    MACD Histogram 0.0668
    Fundamentals Value
    Market Cap 99.06 Million
    Num Shares 34.4 Million
    EPS -2.89
    Price-to-Earnings (P/E) Ratio -1.00
    Price-to-Sales 266.16
    Price-to-Book 5.21
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.23
    Resistance 3 (R3) 3.26 3.19 3.17
    Resistance 2 (R2) 3.19 3.10 3.17 3.15
    Resistance 1 (R1) 3.03 3.04 3.00 3.00 3.13
    Pivot Point 2.96 2.96 2.94 2.94 2.96
    Support 1 (S1) 2.80 2.87 2.77 2.77 2.63
    Support 2 (S2) 2.73 2.81 2.71 2.61
    Support 3 (S3) 2.57 2.73 2.59
    Support 4 (S4) 2.54